Power3 Medical Products Advances The Diagnostic Capabilities Of The Company’s Alzheimer’s Disease Biomarkers
July 15th, 2008 | by admin |Power3 Medical Products, Inc. (OTCBB:PWRM) announced the filing of a US Patent application for the diagnosis of multiple forms of Alzheimer’s disease by monitoring a panel of protein biomarkers in human blood serum. This latest filing further extends the reach of the recently filed US Utility Patent Application that identified 47 protein biomarkers useful in the early diagnosis of Alzheimer’s disease.
Because early signs of AD are often hard to distinguish from normal signs of aging, most patients are not diagnosed until neuronal damage is extensive. A diagnostic test that will allow physicians to diagnose AD patients earlier and with greater accuracy would enable those patients to begin drug treatment when it could be most effective. More than 18 million people world-wide have Alzheimer’s disease. This figure is projected to nearly double to 34 million by 2025.
“One of the most critical issues in medicine is the ability to distinguish Alzheimer’s disease from other forms of dementia and other neurological and vascular disorders that have similar symptoms, but are different diseases with different causes, prognoses, and treatments. This issue is further complicated by the fact that there are also multiple forms of Alzheimer’s disease that are driven by distinct variations in the disease mechanism,” said Dr. Ira L. Goldknopf, Power3’s Director of Proteomics.
This new application discloses how a select group of the protein biomarkers of neurodegenerative disease in the blood may be employed to distinguish between patients with different forms of Alzheimer’s disease (AD). These biomarkers may also enhance the sensitivity and specificity of diagnosis, to monitor disease severity, progression, and response to treatment as well as detect and monitor disease processes and mechanisms.
“The discoveries outlined in this patent application, based on our many years of pioneering proteomics experience, are critical to the value of our intellectual property and essential for developing high-throughput commercial diagnostic tests for early detection. We see potential use of these biomarkers as a companion diagnostic for screening prospective clinical trial patients, monitoring the progress of patients during treatment or clinical trials and as targets in the discovery of new drugs,” said Steven B. Rash, Power3’s CEO.
About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM, http://www.Power3Medical.com) is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro™, in twelve Middle Eastern countries. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Power3 Medical Products
Stumble it!
